2002PubMedOpen access

What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).

Eric Wooltorton

Open full text 21 citations

Abstract

Reason for posting: NSAIDs are useful in the treatment of several musculoskeletal conditions[1][1] and primary dysmenorrhea,[2][2] but they are associated with significant gastrointestinal events.[1][1] Selective cyclooxygenase-2 (COX-2) inhibitors such as rofecoxib (Vioxx) and celecoxib (Celebrex)

About this research paper

What this paper is about

Reason for posting: NSAIDs are useful in the treatment of several musculoskeletal conditions[1][1] and primary dysmenorrhea,[2][2] but they are associated with significant gastrointestinal events.[1][1] Selective cyclooxygenase-2 (COX-2) inhibitors such as rofecoxib (Vioxx) and celecoxib (Celebrex)

Why it matters

OpenAlex reports 21 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Reason for posting: NSAIDs are useful in the treatment of several musculoskeletal conditions[1][1] and primary dysmenorrhea,[2][2] but they are associated with significant gastrointestinal events.[1][1] Selective cyclooxygenase-2 (COX-2) inhibitors such as rofecoxib (Vioxx) and celecoxib (Celebrex)

Key concepts: Rofecoxib, Celecoxib, Medicine, Prostaglandin-Endoperoxide Synthase, Cyclooxygenase, Pharmacology, Chemistry, Enzyme

Related papers

Back to paper searchBrowse research topicsOriginal source
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). — Research Paper | ScholarLens